Our Mission

Today, 5-year survival for children diagnosed with acute lymphoblastic leukemia (ALL) is over 90% – a result of a lengthy frontline chemotherapy regimen. Unfortunately, not all patients respond so favorably; whether or not they have effective standard treatment options available after frontline therapy depends on their subtype of acute lymphoblastic leukemia. Those patients with B-cell ALL have several targeted therapies available; while those patients with T-cell ALL have no effective standard therapy. Allterum is seeking to change this, by developing a targeted therapy for the treatment of pediatric patients with relapsed or refractory T-cell ALL.

image

Relapsed/Refractory T-cell ALL

Patients with relapsed/refractory T-cell ALL are rare - only about 150 patients each year. Yet these patients deserve effective therapeutic options.

image

Frontline Therapy for ALL

Pediatric cases make up the vast majority of ALL diagnoses. Although current chemotherapy is very effective, lifelong side-effects from chemotherapy can be debilitating. Allterum seeks to expand our therapy into frontline combinations with the goal of improving response rates above 90%, while diminishing the toxic burden of current treatments.

image

Lymphomas and other T-cell Diseases

Allterum is actively identifying other cancers of T-cell origin where patients may benefit from treatment with our monoclonal antibody.

PARTNERSHIPS & COLLABORATIONS

ALLTERUM THERAPEUTICS, is a bio-pharmaceutical company developing a monoclonal antibody therapy for pediatric acute lymphoblastic leukemia. Allterum was founded in 2018 out of Fannin Innovation Studio in Houston, TX.

GET IN TOUCH

Thank you for your interest in Allterum. Got a question? We'd love to hear from you. Send us a message and we'll respond as soon as possible.

GET IN TOUCH

Thank you for your interest in Allterum. Got a question? We'd love to hear from you. Send us a message and we'll respond as soon as possible.